---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-001622"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-08T23:27:13.984078+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Alnylam Q3 2023 net product revenues $313M (+35% YoY); FDA CRL for ONPATTRO cardiomyopathy

## Summary
- Q3 net product revs $313M (+35% YoY); GAAP net income $147.8M ($1.15 diluted EPS) vs loss of $405.9M in Q3 2022.
- FDA issued Complete Response Letter for patisiran (ONPATTRO) sNDA for ATTR cardiomyopathy.
- Positive topline results from KARDIA-1 Phase 2 study of zilebesiran in hypertension; entered global collaboration with Roche.
- Updated 2023 guidance: collaboration & royalty rev $575-625M; net product rev reiterated at $1,200-1,285M.

## SEC filing metadata
- accession: 0001157523-23-001622
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000115752323001622/0001157523-23-001622-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000115752323001622/a53737945.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-001622
- JSON: https://secwatch.observer/filing/0001157523-23-001622.json
- Plain text: https://secwatch.observer/filing/0001157523-23-001622.txt

## Key facts
- Earnings Releases
  ALNYLAM PHARMACEUTICALS, INC. reported third quarter ended September 30, 2023 results: revenue $313 Million, net income $147,753, EPS $1.18.
  - Period: third quarter ended September 30, 2023
  - Revenue: $313 Million
  - Net income: $147,753
  - EPS: $1.18
  - Result: reported results
  source text: Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity − Achieved Third Quarter 2023 Global Net Product Revenues of $313 Million, Representing 35% Year-Over-Year Growth Compared to Q3 2022 –
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178670/000115752323001622/0001157523-23-001622-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.